.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB04_Enzalutamide.Enzalutamide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB04_Enzalutamide.Enzalutamide| name: | Enzalutamide |
| ATC code: | L02BB04 | route: | oral |
| n-compartments | 2 |
Enzalutamide is a non-steroidal antiandrogen medication approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It acts by inhibiting the androgen receptor and is used as an oral therapy in advanced prostate cancer settings.
Population pharmacokinetic parameters reported for adult male patients with metastatic castration-resistant prostate cancer receiving oral enzalutamide 160 mg once daily.
Liu, YM, et al., & Chen, Q (2019). Pharmacokinetics and Safety of Enzalutamide in Healthy Chinese Male Volunteers. Clinical therapeutics 41(2) 261–268. DOI:10.1016/j.clinthera.2018.12.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30642613
Lennep, BW, et al., & Morgans, AK (2024). Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy. Drug safety 47(7) 617–641. DOI:10.1007/s40264-024-01415-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38607520
George, DJ, et al., & Shore, ND (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clinical genitourinary cancer 21(3) 383–392.e2. DOI:10.1016/j.clgc.2023.03.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37062659